Amniotic Membrane Market Size & Outlook, 2026-2034

Amniotic Membrane Market Overview

The amniotic membrane market size is valued at USD 4.28 billion in 2025 and is estimated to reach USD 13.04 billion by 2034, growing at a CAGR of 13.20% during the forecast period. The amniotic membrane market is witnessing significant growth due to increasing awareness about the benefits of amniotic membrane treatments in wound healing, surgical procedures, and regenerative medicine. 

Key Market Trends & Insights

• The North America amniotic membrane market dominated the overall global market and accounted for a 34.5% revenue share in 2025.
• The Asia-Pacific region is expected to witness the highest growth rate of 14.5% during the forecast period.
• By product, the cryopreserved amniotic membrane segment held the largest market share, accounting for 60.1% in 2025.
• By application, the ophthalmology segment is anticipated to witness the fastest CAGR of 15% during the forecast period.
• By end-use, the hospitals segment accounted for the largest revenue share of 40% in 2025.
• The U.S. amniotic membrane market held a significant share of North America's market in 2025.

Market Revenue Figures

• 2025 Market Size: USD 4.28 billion
• 2034 Projected Market Size: USD 13.04 billion
• CAGR (2026-2034): 13.20%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The amniotic membrane is a thin, nutrient-rich tissue that protects the fetus and is widely used after childbirth for its regenerative and healing properties. Demand is rising as regenerative medicine expands, utilising tools such as stem cells, tissue engineering, and biomaterials to repair damaged tissues. Amniotic membranes are valued for their ability to reduce inflammation, support cell growth, and accelerate healing. Growth is further supported by the rising prevalence of chronic wounds, advancements in biotechnology, and increasing awareness among clinicians and patients. Training programs and medical conferences are enhancing clinician adoption, while improved access to medical information is increasing patient demand for advanced, biologically active therapies.

Latest Market Trends

Expanded Adoption in Ophthalmology

A major trend in the amniotic membrane market is its expanding use in ophthalmology. The membrane’s natural healing, anti-inflammatory, and anti-scarring properties make it highly effective in repairing corneal defects, performing pterygium surgery, and reconstructing the ocular surface. Its ability to support epithelial regeneration and reduce postoperative complications has strengthened its role in eye-care procedures. Continued advancements in ophthalmic surgical techniques and an improved understanding of the membrane’s therapeutic benefits are driving wider adoption.

Technological Advancements in Medical Procedures

The integration of advanced technologies is leading to the development of amniotic membranes with enhanced efficiency and efficacy. Modern techniques ensure that essential growth factors and healing properties are maintained, enhancing their applicability in various medical domains. The compatibility of the amniotic membrane with cutting-edge treatments, such as stem cell therapies and three-dimensional (3D) bioprinting, is offering a favourable market outlook. Stem cell treatments, in particular, are experiencing increased adoption due to strong clinical evidence supporting their effectiveness, which is contributing to the growth of the market.

To get more insights about this report Download Free Sample Report

Market Driver

Increasing Demand for Regenerative Medicine

The rising prevalence of several chronic conditions like diabetes and rheumatoid arthritis, leading to chronic wounds and ulcers, is increasing the need for effective treatment methods. Amniotic membranes offer an innovative solution and stimulate the healing process. Apart from this, the growing global geriatric population, which is highly susceptible to various health conditions, is driving the need for treatments that promote faster healing and tissue regeneration.

Furthermore, the increasing adoption of amniotic membranes in various medical specialities, such as orthopaedics and dental medicine, is positively impacting the amniotic membrane market outlook. Moreover, the amniotic membrane's ability to facilitate cellular growth and decrease inflammation is driving its adoption in other regenerative treatments.

Market Restraint

High cost of amniotic products and treatments

High costs remain one of the most significant restraints in the amniotic-products market. Amniotic membranes and related biologic products are expensive primarily because they require complex processing, including donor screening, serological testing, sterilisation, preservation and strict quality-control procedures to ensure safety and efficacy. These steps make manufacturing highly resource-intensive, and the expenses are passed down to healthcare providers and patients. In many countries, limited reimbursement coverage further increases out-of-pocket expenses, making treatments unaffordable in cost-sensitive healthcare systems. As a result, the high price of amniotic products restricts their widespread clinical adoption and slows market penetration, especially in developing regions.

Market Opportunity

Expanding Scope of Chronic Wound Care

The growing burden of chronic wounds presents a strong opportunity for amniotic membrane adoption. Rising global cases of diabetes, vascular disorders, pressure ulcers, and age-related healing challenges are driving demand for advanced biological treatments. Amniotic membranes offer natural anti-inflammatory, antimicrobial, and regenerative properties that promote faster healing in diabetic foot ulcers, venous leg ulcers, and pressure sores. Their ability to reduce healing time, lower infection risk, prevent amputations, and reduce overall treatment costs positions amniotic membranes as a key solution in chronic wound care.

Regional Analysis 

The North America amniotic membrane market led the global market in 2025, capturing 34.5% of total revenue. A well-developed healthcare infrastructure, combined with the strong presence of major market players, drives the region's growth. Rising emphasis on regenerative medicine and the swift adoption of advanced technologies are further accelerating market expansion. Moreover, favourable regulatory conditions and sustained R&D investments underpin the region’s strong market outlook for the forecast period.

• The U.S. is the leading country in the North American amniotic membrane market, primarily due to its highly developed healthcare infrastructure, widespread availability of advanced medical technologies, and strong presence of major industry players. The country’s rapid adoption of regenerative medicine, along with its robust clinical research ecosystem, continues to drive demand for innovative amniotic membrane–based therapies in both ocular and wound care applications.

Asia Pacific Market Insights

The Asia Pacific amniotic membrane market is projected to register the fastest growth at a CAGR of 14.5% during the forecast period, with China and Japan anticipated to lead regional expansion. Growth in the area is supported by a rising pool of skilled medical professionals and the ongoing development of healthcare infrastructure. Additionally, increasing awareness of the therapeutic benefits of amniotic membranes is expected to accelerate market adoption further and drive overall regional growth.

• China’s market is expected to witness substantial growth throughout the forecast period. The continuous expansion of healthcare infrastructure, coupled with a growing and increasingly skilled medical workforce, is enhancing the capacity to adopt advanced therapeutic solutions, including amniotic membrane–based treatments. Well-established medical facilities, particularly in urban and semi-urban regions, further facilitate the adoption and application of these products in clinical settings.

Europe Market Insights

Europe’s market is projected to experience steady growth over the forecast period, supported by the region’s advanced healthcare infrastructure, high-quality medical facilities, and well-trained healthcare professionals. Countries such as Germany, France, and the UK are leading the adoption of amniotic membrane–based therapies due to their focus on regenerative medicine and wound care innovations. Additionally, rising awareness among clinicians and patients regarding the clinical benefits of amniotic membrane applications, coupled with continuous investment in research and development, is expected to enhance market expansion.

• Germany’s amniotic membrane market is largely driven by the expanding ophthalmology sector. Amniotic membranes are increasingly employed in the treatment of ocular surface disorders, corneal defects, and other ophthalmic conditions. The market growth is further supported by advancements in biotechnology, rising awareness among healthcare professionals about the clinical benefits of these therapies, and growing patient demand for effective, non-invasive treatment options.

Latin America Market Insights

The Latin American amniotic membrane market is expected to experience consistent growth throughout the forecast period, fueled by improvements in healthcare infrastructure and the increasing use of advanced therapies in wound care and ophthalmology. Brazil and Mexico are likely to dominate the regional market, thanks to well-developed medical facilities, a growing pool of trained healthcare professionals, and heightened awareness of the benefits of amniotic membrane treatments. Rising rates of chronic wounds, surgical interventions, and ocular disorders are further driving demand.

• Brazil is the dominant country in the market, serving as the primary driver of regional growth. The country benefits from a well-established healthcare infrastructure and a network of advanced medical facilities, which support the adoption of innovative therapies, including amniotic membrane products. A rising prevalence of chronic wounds, ocular disorders, and surgical interventions has significantly increased demand for effective regenerative and wound-healing solutions.

Middle East and Africa Market Insights

The Middle East & Africa amniotic membrane market is expected to register moderate growth over the forecast period, fueled by factors such as increasing living standards, higher healthcare expenditure, and the presence of well-developed medical infrastructure. The rising prevalence of cancer, along with a growing emphasis on early detection and treatment, is anticipated to drive demand for amniotic membrane therapies. Additionally, government initiatives aimed at expanding reimbursement coverage and improving healthcare accessibility are likely to foster greater market adoption and bolster overall market growth in the region.

• Saudi Arabia leads the market, driven by advanced healthcare infrastructure, high medical spending, and rising demand for regenerative and wound-healing therapies. Supportive government initiatives, increasing prevalence of chronic conditions, and growing awareness of clinical benefits further strengthen the country’s dominant position in the region.

Product Insights

Cryopreserved Amniotic Membrane accounted for the highest revenue share of 60.1% in 2025. Its high effectiveness and widespread adoption rate worldwide made it the most popular. These membranes are preserved at very low temperatures (e.g., −80 °C), retaining histological properties that support inflammation reduction and faster healing. Their clinical effectiveness and broad adoption in complex surgeries ensure continued leadership.

The dehydrated amniotic membrane segment is projected to be the fastest-growing, with a CAGR of 9.4% by 2025. They are used for the treatment of various surgical wounds, including reconstructions and pressure ulcers on the legs. These are typically used as biological bandages to encourage healing. Some examples of commercially available dehydrated amniotic fluids include FloGraft (PalinGen), AmnioFix (AmbioDisk), and AmnioDisk (AmbioDisk). With easier storage and handling at ambient temperatures, these products are gaining traction, especially in outpatient and ambulatory settings.

Application Insights

The surgical wounds segment holds more than 40.2% of the total revenue in 2025. These membranes can also be used in reconstructive surgery to promote healing and decrease scarring. Amniotic membranes are a great way to reduce scarring, speed up healing and lower the risk of infection. These products are in high demand due to the growing popularity of cosmetic surgery. The growth is driven by increasing global surgical volumes, cosmetic procedures, and the growing need for complex wound care.

The ophthalmology segment is expected to register the highest CAGR of 15% during the forecast period. Amniotic membranes are extensively employed in the management of ocular surface disorders, including corneal ulcers, persistent epithelial defects, and chemical injuries. Their anti-inflammatory, anti-scarring, and regenerative properties facilitate faster healing while reducing the likelihood of infection and scar formation, making them a critical component of advanced eye care.

End Use Insights

The hospitals segment represents the largest end-use category, accounting for 40% of the amniotic membrane market in 2025, driven by the high volume of surgical procedures and complex wound care cases managed in these settings. The availability of advanced infrastructure, skilled healthcare professionals, and established procurement systems in hospitals facilitates the adoption of these biologic products, making this segment the primary contributor to market revenue.

The Ambulatory Surgical Centres (ASCs) segment is experiencing rapid growth, with a CAGR of 11.8%, driven by the increasing preference for outpatient procedures and minimally invasive treatments. ASCs utilise amniotic membranes in various applications, including ophthalmic surgeries, wound management, and regenerative medicine, to promote faster healing, minimise scarring, and enhance patient outcomes. The efficiency, convenience, and cost-effectiveness of outpatient care are driving the increasing adoption of these biologic products in ASCs.

Competitive Landscape

The amniotic membrane market is moderately consolidated, characterised by ongoing innovations, product segmentation, and increased spending on clinical studies. Players are working to enhance sophisticated preservation technologies and build uses in surgical practices, wound care, and ophthalmic practices. Regulation permits and quality approval remain instrumental for determining credibility as well as attaining market penetration. Hospital, research centre, and surgery centre partnerships are emerging as new ways to expand customer bases.

Competition also exists based on the type of membrane (cryopreserved or dehydrated), with companies seeking to enhance shelf life and therapeutic effectiveness. 

MiMedx Group, Inc.- A Market Leader

MiMedx Group Inc. is a company that focuses on the development and distribution of placental biologics. The company provides innovative solutions for wound care, burn treatment and surgical recovery. It offers a range of products, such as Epifix, Epicord, and Amniofix, among others, which are used in advanced wound and surgical applications. The company’s products are utilised by healthcare professionals, including surgeons and wound care clinicians, to treat patients across various medical fields such as plastic surgery, vascular surgery, and orthopaedic surgery.

Latest News

• In October 2025, MiMedx Group, Inc. launched EPIXPRESS, a next-generation lyophilised (dehydrated) human placental allograft. The product builds on the existing EPIEFFECT, incorporating fenestrations to facilitate better fluid movement and wound management.

List of key players in Amniotic Membrane Market

1. Biotissue Surgical Inc.
2. Amnio Technology LLC
3. Applied Biologics LLC
4. BIOHEALING SRO
5. Celularity Inc.
6. Flower Orthopaedics Corp.
7. Human Regenerative Technologies LLC
8. Integra Lifesciences Corp.
9. Katena Products Inc.
10. Merakris Therapeutics Inc.
11. MiMedx Group Inc.
12. Next Biosciences Pty Ltd.
13. NuVision Biotherapies Ltd
14. Organogenesis Holdings Inc.
15. Orthofix Medical Inc.
16. Reea Carewell products
17. Skye Biologics Holdings LLC
18. Stryker Corp.
19. Surgenex LLC
20. SURGITECH INNOVATION

To get more findings about this report Download Market Share

Strategic Initiatives

• July 2025 - MiMedx Group, Inc. announced a strategic collaboration with Vaporox, Inc., which focuses on Vaporous Hyperoxia Therapy (VHT) devices.
• March 2025 - BioTissue announced that its birth tissue donation program, Sharing Miracles, will collaborate with Mount Sinai Medical Centre to launch a groundbreaking program designed to streamline the birth tissue donation process at the Miami hospital.